Compare Vipshop Holdings Ltd - ADR (VIPS) vs Viatris Inc (VTRS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Vipshop Holdings Ltd - ADR vs Viatris Inc — how do they compare? Vipshop Holdings Ltd - ADR trades at $14.52 (market cap $7.20B), while Viatris Inc trades at $16.15 (market cap $18.69B). The key difference: Viatris Inc is far larger — about 2.6× Vipshop Holdings Ltd - ADR's market cap, and Vipshop Holdings Ltd - ADR pays the higher dividend (4.14%). Which is the better fit depends on your goals.
| VIPS | VTRS | |
|---|---|---|
Market Cap | $7.20B | $18.69B |
Sector | Consumer Cyclical | Health |
52-Week High | $20.68 | $17.86 |
52-Week Low | $12.92 | $9.49 |
Enterprise Value | $3.76B | $30.80B |
Dividend Yield | 4.14% | 2.95% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Vipshop (VIPS) trades at $14.49, down 5.97% over 24 hours, with a bullish technical signal from moving averages but mixed oscillators. The stock shows attractive valuation metrics, including a P/E of 6.79 and P/S of 0.48, alongside strong profitability with an 18.43% ROE. Recent earnings have been mixed, with Q1 2026 EPS meeting expectations, while the company pursues growth through an outlet strategy and REIT spin-off.
The outlook remains positive due to low valuations and profitability, but risks include revenue stagnation and competitive pressures. Analyst consensus is bullish with 53.57% buy ratings, supporting potential upside if earnings growth resumes in 2026.
Viatris (VTRS) trades at $16.105, down 1.07% on the day, with a bearish technical signal and mixed fundamentals. Recent Q2 2026 earnings beat estimates with EPS of $0.69 and revenue growth of 5%, but the company posted a net loss of $3.51B in 2025. Positive developments include FDA approval for Gwyn Lo and a raised 2026 outlook, though debt remains elevated at $14.04B long-term.
Outlook is cautious; while operational cash flow is strong at $2.32B and dividends provide income, persistent net losses and high P/E of 236.2 signal overvaluation risks. Analyst consensus leans Hold (61.54%), with upside potential if turnaround gains traction, but investors face headwinds from generic drug pricing pressures and execution challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Vipshop Holdings Ltd - ADR
Vipshop Holdings Ltd is an online discount retailer for brands in China. The company offers branded products to consumers in China through flash sales on its vipshop.com, vip.com and lefeng.com websites. Flash sales represent an online retail format combining the advantages of e-commerce and discount sales through selling a finite quantity of discounted products or services online for a limited period of time. It deals in a wide range of products and services for consumers specializing in branded cosmetics, apparel, healthcare products, food and other consumer products. Its operating segment includes Vip.com and Shan Shan Outlets. The company generates maximum revenue from Vip.com segment.
Read more on VIPS →About Viatris Inc
Formed by the combination of Mylan and Pfizer's Upjohn business in 2020, Viatris is one of the world's largest generic drug manufacturers, with a substantial off-patent branded drug portfolio. Its portfolio consists of more than 1,400 molecules with penetration across most of the developed world and in select emerging markets. The company's branded drug portfolio consists of off-patent blockbuster drugs that continue to generate strong sales, including Lipitor, Norvasc, Lyrica, Viagra, and EpiPen. While global competition has facilitated the commodification of small-molecule generic drugs, the company has demonstrated an edge over peers in its ability to manufacture complex generics (for example, generic Advair and Copaxone).
Read more on VTRS →
